title: [The pharmacology of endothelin and its antagonist bosentan].
abstract: Endothelin is one of the most potent vasoconstrictors known, but it also plays a role in inflammation, fibrosis and cellular hypertrophy. Endothelin is a key pathogenic factor in congestive heart failure, essential hypertension and pulmonary hypertension. Bosentan is a specific mixed antagonist of endothelin receptors. Preclinical and clinical data suggest that bosentan might become a new approach for the chronic treatment of these cadiovascular and pulmonary diseases.
authors.affiliation: Actelion Ltd., Gewerbestrasse 16, CH-4123 Allschwil, Switzerland.
authors.forename: M
authors.initials: M
authors.lastname: Clozel
authors.forename: S
authors.initials: S
authors.lastname: Roux
mesh_terms: D000818:Animals; D000077300:Bosentan; D065128:Endothelin Receptor Antagonists; D016232:Endothelins / Q000494:pharmacology / Q000502:physiology*; D006333:Heart Failure / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology; D006976:Hypertension, Pulmonary / Q000188:drug therapy / Q000209:etiology; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D065128:Endothelin Receptor Antagonists; D016232:Endothelins; D013449:Sulfonamides; D000077300:Bosentan